Meeting
2017 ASCO Annual Meeting
Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.
Authors
Ryan J. Sullivan
Massachusetts General Hospital Cancer Center, Boston, MA
Ryan J. Sullivan , Rene Gonzalez , Karl D. Lewis , Omid Hamid , Jeffrey R. Infante , Manish R. Patel , F. Stephen Hodi , Jeffrey Wallin , Bethany Pitcher , Edward Cha , Louise Roberts , Marcus Ballinger , Patrick Hwu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research,Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT01656642
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3063)
DOI
10.1200/JCO.2017.35.15_suppl.3063
Abstract #
3063
Poster Bd #
158
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity.
First Author: Wilson H. Miller Jr.
Poster
2013 ASCO Annual Meeting
Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma.
First Author: James M. G. Larkin
Poster
2022 ASCO Annual Meeting
Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma: Interim analysis of the ImmunoCobiVem study.
First Author: Dirk Schadendorf
Poster
2018 ASCO Annual Meeting
Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM).
First Author: Matthew Dankner